An impressive line-up of industry experts have agreed to join a new high-level Scientific Advisory Panel to help drive the British Pharmacological Society’s scientific and research dissemination strategies.
The panel, which will meet for the first time in January 2019, comprises:
- Professor Jackie Hunter, Chief Executive, Clinical Programmes & Strategic Relationships, Benevolent AI
- Dr Fiona Marshall, VP Head of the UK Discovery Centre, MSD Research Laboratories
- Dr Menelas Pangalos, Executive Vice-President, Research & Development BioPharmaceuticals
- Dr Tony Wood, Senior Vice President of Medicinal Science & Technology, GSK
Professor Steve Hill and Professor Sir Munir Pirmohamed, President and President-Elect respectively, will represent the Society on the panel.
The group will advise on the Society’s scientific content strategy, and help to ensure its journals, meetings and policy outputs are aligned. It will have a focus on identifying emerging trends in the life sciences, enabling the Society to better understand how it can integrate these into its future activities and decisions. The panel will also act as a core scientific advisory group for the Society’s annual meeting – Pharmacology – and for the World Congress of Pharmacology, which the Society will be hosting in Glasgow in 2022.
Steve Hill said:
I am delighted that we will now be able to draw on the advice of such a well-respected and well-connected group. We made a conscious decision to assemble a panel that could bring us heavyweight industry expertise, along with knowledge of life sciences policy and regulation at the highest levels.
Allied to the clinical and basic pharmacology expertise that Munir and I will bring to the table, this is a group that I am confident will be able to give us a 360° insight into the current – and, crucially – future life sciences landscape.
Tony Wood said:
This is an exciting time for science, drug discovery and development, and the British Pharmacological Society plays an important role by focusing on some of the most important health issues faced by society, such as the global challenge of antimicrobial resistance and supporting the next generation of scientists, to ensure we can continue to make life-saving medicines. I am thrilled to join their new Scientific Advisory Panel, sitting alongside other UK industry and academic leaders, to consider how emerging scientific trends and policy challenges can be addressed through their future work, as it is critical that we retain the UK’s position as a centre for scientific excellence.
Fiona Marshall said:
As a fellow of the Society and a member for many years I am delighted to join the new Advisory Panel with other leaders from UK science and industry. Pharmacology plays a critical role in the development of new medicines and I hope this new panel will continue to foster the close interactions the pharmacology community has with the rest of the UK life sciences community.
Menelas Pangalos said:
I am thrilled to be part of this panel, helping to shape the direction of the society as we embrace new and exciting technologies in the discovery of the next wave of innovative medicines for patients.